"We are excited about the potential to bring KIMMTRAK to more patients with melanoma through the Phase 3 TEBE-AM trial that is expected ... For the treatment of HBV, the Company aims to achieve ...
Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million ---- Adult patients with acquired hypothalamic ...
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Collaboration Revenues: Collaboration revenues were $3.7 million for the third quarter of 2024, compared to $4.7 million for the same period of 2023. Collaboration revenues in the third quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback